Expectedly, the “cytotoxic” cluster encompassed known chemotherapeutic agents including the standard AML combination therapy DNR and cytarabine (AraC) or actinomycin D, both of which have been shown to be clinically active in NPM1-mutated AML [20, 21]. Here, NPM1 is linked to acute myeloid leukemia.